Group No Serum β2-M (mg/L,) (mean ± SD) P positive rate (%) P
Controls 1002 0.99 ± 4.47   7.88  
Female benign tumor 141 1.19 ± 2.55 >0.05 20.00 <0.05
Female breast Ca. 201 2.05 ± 4.81 < 0.05 30.84 <0.05
Female breast Ca,          
ages:          
<40years 46 2.51 ± 6.64   39.13  
40-60years 127 2.15 ± 4.47 >0.05 28.34 >0.05
60years 19 0.84 ± 1.75 >0.05 7.14 < 0.01
cilinical stages          
14 1.77 ± 2.48   28.57  
116 2.50 ± 3.61 >0.05 34.48 >0.05
24 2.18 ± 4.15 >0.05 33.33 >0.05
14 0.74 ± 1.85 >0.05 28.57 >0.05
Benign tumor 243 0.68 ± 2.20 >0.05 7.81 >0.05
Thyroid Ca. 95 2.84 ± 4.56 <0.05 34.73 <0.01
Thyroid Ca.:          
Male: 26 1.71 ± 2.88   23.07  
female: 69 3.26 ± 5.00 >0.05 36.23 >0.05
ages:          
<40years 31 2.04 ± 4.35   22.58  
40-60years 45 3.66 ± 4.96 >0.05 46.67 <0.05
60years 19 2.17 ± 3.71 >0.05 26.31 >0.05
cilinical stages          
28 2.07 ± 4.18   28.57  
Ⅱ- Ⅲ 18 2.15 ± 1.674.95 >0.05 33.33 >0.05
20 0.23 ± 1.35 < 0.01 0 <0.01
Cell  types;          
Follicular- -thyroid adenoma 42 2.07 ± 3.75   19.07  
Papillary-thyroid adenoma 18 2.71 ± 4.25 >0.05 44.44 <0.05
Table 3: Mean levels of serum β2-microglobulin in female breast cancer patients , thyroid cancer patients and benign tumor patients.